April C. Braddy
University of Florida
8 Papers
76 Citations
April C. Braddy is an academic researcher from University of Florida. The author has contributed to research in topics: Medicine & Mass spectrometry. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
Micellar Aggregation and Membrane Partitioning of Bile Salts, Fatty Acids, Sodium Dodecyl Sulfate, and Sugar-Conjugated Fatty Acids: Correlation with Hemolytic Potency and Implications for Drug Delivery
Benjamin P. Ross,April C. Braddy,Ross P. McGeary,Joanne T. Blanchfield,Laszlo Prokai,Istvan Toth +5 more
TL;DR: It was concluded that the biocompatibility of liposaccharides can be modulated by minor alterations in nc, and a study of hemolytic activity revealed that liposACcharides with an nc of < or = 12 are the most likely to beBiocompatible.
43
Integration of mass spectrometry into early-phase discovery and development of central nervous system agents.
Laszlo Prokai,Alevtina D. Zharikova,Tamás Janáky,Xiaoxu Li,April C. Braddy,Pál Perjési,Lidia N. Matveeva,David H. Powell,Katalin Prokai-Tatrai +8 more
TL;DR: Making atmospheric-pressure ionization mass spectrometry an integral part of the process has played a major role in increasing throughput, selectivity, specificity and detection sensitivity and thereby providing useful information about the extent or mechanism of transport and metabolic activation/inactivation in early-phase discovery and development of CNS agents.
18
Immobilized artificial membrane chromatography coupled with atmospheric pressure ionization mass spectrometry
TL;DR: Both atmospheric pressure ionization methods permitted the simultaneous determination of the k'(IAM), capacity factors and, therefore, an increased-throughput ranking of potential new leads emerged from the drug discovery process based on affinity to artificial membranes.
16
Reconciling sprinkle administration information in approved NDA labeling with sprinkle bioequivalence study recommendations in FDA product-specific guidances for generic drug development
S. C. Chun,Patrick E. Nwakama,Devvrat T. Patel,Ke Ren,April C. Braddy +4 more
- 19 Dec 2022
TL;DR: In this article , the authors searched the FDA external PSG database for availability of respective PSGs containing in vivo sprinkle study recommendations for those modified-release (MR) RLD products with approved NDA labeling for sprinkle administration.
9
The bioequivalence study design recommendations for immediate-release solid oral dosage forms in the international pharmaceutical regulators programme participating regulators and organisations: differences and commonalities
E. F. Fernandes,Joy van Oudtshoorn,Andrew Tam,Liliana Carolina Arévalo González,Erwin Guzmán Aurela,Henrike Potthast,Katalina Mettke,Ryosuke Kuribayashi,Kohei Shimojo,Mihoko Kasuga,Lázaro Morales,Zulema Rodríguez,Choongyul Ahn,Eunju Yun,So Hee Kim,Clare Rodrigues,Toh Tiong,Christopher Crane,Chantal Walther,Matthias S Roost,Tzu-Ling Chen,Li-feng Hsu,April C. Braddy,Alfredo García-Arieta,Ivana S. Abalos,Milly Divinsky,Abdulaziz Alsuwyeh,Bader Alzenaidy,Adel Alharf +28 more
- 21 Mar 2024
TL;DR: The BEWGG recommendations for immediate-release solid oral dosage forms provide guidance on the conduct and acceptance criteria for BE studies, highlighting similarities and differences among members.
1